NOVEN
NAMES ANTHONY VENDITTI VICE PRESIDENT – MARKETING & SALES |
|
Miami, FL, June 30,
2008 -- Noven Pharmaceuticals, Inc. (NASDAQ: NOVN) today announced
the appointment of senior pharmaceutical executive Anthony Venditti
as its Vice President – Marketing & Sales, effective immediately.
In this role, Venditti will lead all aspects of the marketing and sales
functions at Noven Therapeutics (the company’s specialty pharmaceutical
business unit) and Novogyne Pharmaceuticals (the company’s joint
venture with Novartis Pharmaceuticals Corporation).
Venditti joins
Noven with over 20 years of pharmaceutical marketing and sales experience.
Most recently, he served Novartis Pharmaceuticals Corporation as Vice
President and head of Novartis’ $1.3 billion U.S. Neuroscience
division, where he was responsible for marketing, sales and new product
operations for the central nervous system (CNS) portfolio in the U.S.
Previously, he served Novartis in a number of senior executive positions,
with responsibility for marketing, sales, business analysis, strategic
planning and new product commercialization, including key roles in
the launch of several new products.
"Anthony will direct both
the marketing and the sales functions at Noven Therapeutics and Novogyne,” said
Peter Brandt, Noven’s President & Chief Executive Officer. “He
has a history of success in marketing and sales, expertise in CNS and
other therapeutic areas, and significant experience with new product
launches – all of which make him a great fit with our growth
strategy. He is a proven industry veteran who I expect will help lead
Noven’s evolution from primarily a drug delivery company to a
high growth specialty pharmaceutical company.”
About Noven
Noven Pharmaceuticals, Inc. is a specialty pharmaceutical
company engaged in the research, development, manufacture, marketing
and sale of prescription pharmaceutical products. Noven’s business
and operations are focused in three principal areas – transdermal
drug delivery, the Novogyne joint venture, and its Noven Therapeutics
specialty pharmaceutical unit.
Noven
Contact:
Joseph C. Jones
Vice President – Corporate
Affairs
(305) 253-1916
|
|
Copyright © 2008 Noven
Pharmaceuticals, Inc. All rights reserved. |